Efficacy and safety of iris-supported phakic lenses (Verisyse) for the treatment of high myopia: 5-year results

Purpose Evaluating efficacy and safety of iris-supported phakic lenses (Verisyse) for high myopia treatment. Methods Patients treated with Verisyse (Abbott Medical Optics, Santa Ana, CA, USA) intraocular lens (IOL) implants were evaluated retrospectively. Patients with follow-up periods of more than 5 years were included in the study. Pre- and postoperative fifth-year spheric equivalent (SE) of manifest refraction values, uncorrected and corrected distance visual acuities (UDVA and CDVA, respectively), and endothelial cell density (ECD) values were recorded. Complications were evaluated. Results Forty-seven eyes of 31 patients were included in the study. Pre- and postoperative fifth year mean SE was − 12.50 ± 3.51D and − 0.72 ± 0.40D, respectively. Pre- and postoperative fifth-year UDVA was 1.56 ± 0.22 and 0.33 ± 0.18 logMAR ( p 0,05). The efficacy index (ratio of mean postoperative UDVA to mean preoperative CDVA) of the patients was 1.14 ± 0.60. The mean postoperative endothelial cell loss at 5 years was −7.42%. None of the patients had lost 25% of their preoperative endothelial cells at 5-year follow-up. The mean postoperative endothelial cell loss was −3.05% at 1 year, −1.23% between years one and three, −1.02% between the third and fifth years. Conclusion Verisyse IOL implantation is an effective and safe for high myopia surgical treatment. However, the 5-year follow-up period is not sufficient to evaluate the safety profiles in terms of endothelial cells.